PeerVoice Oncology & Haematology Audio

Mar 05 2025 119 ep. 29 mins 501
PeerVoice Oncology & Haematology Audio Podcast artwork

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Mar 05 2025 20 mins  
Visit https://www.peervoice.com/JJY860 to view the entire programme with slides. After completing “Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions”, participants will be able to: Recognise the significant symptom- and treatment-related burdens associated with cytopenic myelofibros

Albrecht Stenzinger, MD - Optimising the Molecular Profiling Journey for Patients With CCA: Applying Best Practices and Avoiding Pitfalls

Jan 13 2025 25 mins  
Visit https://www.peervoice.com/YDE860 to view the entire programme with slides. After completing “Albrecht Stenzinger, MD - Optimising the Molecular Profiling Journey for Patients With CCA: Applying Best Practices and Avoiding Pitfalls”, participants will be able to: Explain the rationale and current guidelines for molecular testing and targeted treatment of cholangiocarcinoma

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Dec 27 2024 42 mins  
Visit https://www.peervoice.com/YJY860 to view the entire programme with slides. After completing “Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC”, participants will be able to: Summarise the unmet needs in the management of patients with relapsed or refractory (R/R) metastatic colorectal cancer (mCRC);

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Dec 13 2024 55 mins  
Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, participants will be able to: Explain the key characteristics of an oncolytic immunotherapy for advanced melanoma; Discuss the rationale for combini

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Dec 12 2024 19 mins  
Visit https://www.peervoice.com/YVF860 to view the entire programme with slides. After completing “Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer”, participants will be able to: Identify common adverse events associated with the use of TROP2-directed agents in the management of adv

John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Nov 21 2024 20 mins  
Visit https://www.peervoice.com/TBB860 to view the entire programme with slides. After completing “John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis”, participants will be able to: Recognize the significant symptom- and treatment-related burdens associated with cytopeni

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Nov 15 2024 18 mins  
Visit https://www.peervoice.com/KAX860 to view the entire programme with slides. After completing “Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours”, participants will be able to: Discuss best practices in HER2 testing of solid tumours; and Interpret the clinical significance of HER2 scores on therapeutic management.

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Nov 15 2024 20 mins  
Visit https://www.peervoice.com/TUH860 to view the entire programme with slides. After completing “Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML”, participants will be able to: Recall clinical trial data evaluating first- and second-generation FLT3 inhibitors in the management of newly diagnosed F

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Nov 08 2024 57 mins  
Visit https://www.peervoice.com/JQU860 to view the entire programme with slides. After completing “Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice”, participants will be able to: Recognise the role of HER2 as a target in cancer sites beyond breast and gastric; Explain the HER2 testing and sc

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Nov 08 2024 47 mins  
Visit https://www.peervoice.com/SYP860 to view the entire programme with slides. After completing “Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED”, participants will be able to: Evaluate current guidance for management of life-threatening bleeding in patients receiving direct oral antic